Peptide RX

back to claim graph

proof receipt / fold

SIRT3 WT

Structure prediction with public confidence context.

grade B status complete receipt 6cc96606a188 proof 67%

what this node claims

SIRT3 WT

Structure prediction with public confidence context.

Open source surface

vertical proof spine

  1. 01 SIRT3 WT fold / grade B / 62% 2 debt
  2. 02 AlphaFold metrics / SIRT3 alphafold metric / grade B / 70% 1 debt
  3. 03 Initial digest — SIRT3 finding / grade C / 47% 1 debt
  4. 04 fold.complete timeline event / grade C / 55%
  5. 05 SIRT3 target / grade B / 70% 1 debt

evidence / risk instrument

49%
thin proof
structure evidence gates risk export lineage 49
visible debt pressure 47%
75%structureusable
pLDDT 75.35
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
67%lineageusable
incomplete spine

proof completeness

67% missing candidate, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

confidence band
confident
confidence pct
75.35
coverage available
false
gene
SIRT3
has structure
true
pae available
false
plddt avg
75.35
sequence length
0
variant
WT

AlphaFold metrics visual

Confident backbone model

75.3

399 residues / min 22.61 / max 98.94 / source alphafold db

PAE matrix for linked target
Very high 58.9% 235 residues / >=90
Confident 7.0% 28 residues / 70-89
Low 5.0% 20 residues / 50-69
Very low 29.1% 116 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 399 of 399 residues.

  • residues 1-121 / mean 34.62
  • residues 157-167 / mean 66.2
  • residues 396-399 / mean 47.16
proof debt register

Visible limits, not hidden cleanup.

47%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

low computational-only status add independent evidence, challenge result, or witness review before strengthening
medium no candidate yet leave visible until a stronger public receipt resolves it
medium missing PAE/context where AlphaFold DB is not linked attach pLDDT series, PAE matrix, or coverage evidence
high low evidence grade attach graded finding with source-linked evidence
medium missing functional-site annotations link target annotation, GO term, or binding-site context

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it
missing PAE/context where AlphaFold DB is not linked medium visible weakens attach pLDDT series, PAE matrix, or coverage evidence
low evidence grade high blocks weakens attach graded finding with source-linked evidence
missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context

what supports it

target has structure prediction target:d0f97b59-c51b-423b-b74b-ff05c612f60d -> fold:016a173b-c582-419f-bc97-d0cd9bee003f folds_to / B / 0.753

what it supports

measured by AlphaFold confidence context fold:016a173b-c582-419f-bc97-d0cd9bee003f -> alphafold_metric:016a173b-c582-419f-bc97-d0cd9bee003f measured_by / B / 0.753
evidence finding attached fold:016a173b-c582-419f-bc97-d0cd9bee003f -> finding:07abd3f4-4960-4dde-a375-2e9e5634509c supports / C / 0.6
timeline records state change fold:016a173b-c582-419f-bc97-d0cd9bee003f -> timeline_event:29 records / C / 0.5

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.